Back to search
Thyroid Carcinoma, Nonmedullary
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Thyroid Carcinoma, Nonmedullary trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Thyroid Carcinoma, Nonmedullary trials you may qualify forThe purpose of this research is to find new predisposition genes for differentiated thyroid cancer (DTC).
Tumor-related inflammation is one of the hallmarks of cancers in general. Innate immunity specifically is a common denominator which is involved in the pathogen…
The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR)…
Non-medullary thyroid carcinoma has a good prognosis in most patients. However, a small subset of patients nevertheless develop metastatic or locally advanced a…
Blood will be drawn 1 month before and 2 month after regular radioactive iodine treatment. Monocytes will be isolated. The three main outcomes are whole blood c…
This study investigates the reprogramming of myeloid cells in patients with thyroid carcinoma. The investigators hypothesize that tumor-derived factors change t…
This phase I trial is studying the side effects of gefitinib in treating patients with metastatic or unresectable head and neck cancer or non-small cell lung ca…
The purpose of this study is to assess whether therapy with Sorafenib reinduces radioiodine uptake in thyroid carcinoma.